Candel Therapeutics reported an increase in overall survival in the phase 2 clinical trial of Can-2409 for advanced non-small cell lung cancer (Nsclc) in patients unresponsive to immune checkpoint inhibitors (Ici) treatment at the 2024 Asco Annual Meeting
Candel Therapeutics在2024年Asco年会上报告称针对对免疫检查点抑制剂（Ici）治疗无反应的患者的晚期非小细胞肺癌（Nsclc）的Can-2409的2期临床试验的总存活率延长
Candel Therapeutics reported an increase in overall survival in the phase 2 clinical trial of Can-2409 for advanced non-small cell lung cancer (Nsclc) in patients unresponsive to immune checkpoint inhibitors (Ici) treatment at the 2024 Asco Annual Meeting
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.